Mycoplasma pneumonia (MP), is a bacteria that causes a respiratory infection and can causes infection easily once it comes in contact with respiratory fluids causing mycoplasma pneumonia. Mycoplasma pneumonia bacteria are contagious, and can easily get transmitted through the air. In recent times, mycoplasma diagnostics is been observed as a rapidly progressing and rising area in the in-vitro diagnostic industry. For the earlier stage diagnosis of MP, the specialist uses a stethoscope to notice the undesirable sounds in a person’s chest. For further diagnosis, the medical practitioner performs chest X-rays, CT scan or blood tests for the detection of infection.
Get Sample Report with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-sample/763
Therapists and researchers are assuming that mycoplasma diagnostics market will gain enormous growth opportunities in the years to come. According to the World Health Organization (WHO), which is concerned with international public health, there are nearly 600 diagnosis centers and around 200 independent working laboratories to reach mycoplasma diagnosis in the United States. Moreover, in Austria, there is public funding agenesis, such as the Austrian Research Promotion Agency (FFG) which invests partly in R&D for MP Diagnosis.
Rising lung and respiratory disease to propel the market growth of Mycoplasma Diagnostics
Growing incidents of respiratory tract infections around the globe are expected to increase in demand for better diagnosis towards non-pulmonary treatments which would fuel the global market growth in nearby future. According to the Forum of International Respiratory Society 2014, the number of deaths due to respiratory diseases, pulmonary sickness, and tuberculosis have been increased and these numbers are expected to raise in upcoming years, which is expected to boost the growth of mycoplasma diagnostics market.
Increasing geriatric population with respiratory disease is the other major factor propelling market growth. According to the World Health Organization (WHO), 34.3% of the geriatric population was suffering majorly from respiratory tract infection and lung cancer. In-order to overcome chronic respiratory disorders, effective mycoplasma diagnosis is essential, which would eventually boost the mycoplasma diagnostics market globally.
Lack of awareness towards Mycoplasma Diagnostics devices restraining the growth of mycoplasma diagnostics device market
On the other hand, lack of awareness regarding the advantages of the diagnosis is the main factor to restrain growth. Moreover, the cost is another major factor hampering the market growth of mycoplasma diagnosis devices.
Growing needs for better techniques in the Mycoplasma Diagnostics market industry to be a major market driver
According to WHO 2016, advanced techniques such as Polymerase Chain Reaction (PCR), DNA staining and Immunoassay have dominated the market. However, remarkable growth is observed in the use of techniques, such as ELISA and RIA. These techniques are cost-effective and they are used in pharmaceutical and diagnostic industries, due to their ease of use and availability.
Purchase This Premium Report Here To Access Full Information @ https://www.coherentmarketinsights.com/insight/buy-now/763
Mycoplasma Diagnostics Market-Regional Analysis
Based on regions the mycoplasma diagnostics market is segmented as, North America, Europe, Middle East Africa, Asia Pacific, and Latin America
According to the World Health Organization (WHO) 2015, North America holds a 35.6% share of markets leading overall global marketing for Mycoplasma diagnostics. However, according to WHO 2016, around 7.4 million people were reported to have mycoplasma disease in the Asia Pacific region, which is expected to increase in the upcoming future. Asia Pacific region is expected to show lucrative opportunities in mycoplasma diagnostics Market are owing to the rising cases of respiratory tract infection as well as the increasing mortality rate. Key players along with the government of this region is expecting more opportunities in Asia Pacific regions in upcoming years.
Mycoplasma Diagnostics Device Market-Competitive landscape
The major key players in the global mycoplasma diagnostics market industry are Agilent Technologies, American Type Culture Collection (ATCC), Thermo Fisher Scientific, Takara Holding, PromoCell GmbH, Merck KGaA, Lonza Group, Savyon Diagnostics, Tecan Group, Charles River Laboratories International, F Hoffmann-La Roche, and Sartorius Stedim BioOutsource. Major role players in the global mycoplasma diagnostics industries, such as Thermo Fishers Scientifics and Merck KGaA holds around 23% share in the global market, which increases the opportunities towards the profitable and global market insights in Mycoplasma Diagnostics.
In May 2019, QIAGEN launched QIAstat-Dx syndromic testing after receiving 510(k) clearance by the U.S. Food and Drug Administration, QIAstat-Dx Respiratory Panel for simultaneous qualitative detection and identification of multiple respiratory viral and bacterial pathogens.
In July 2018, ATCC, launched its new PCR-based service to detect mycoplasma contamination in cell cultures. This growing service portfolio is part of a larger effort by ATCC to support the authentication of cell lines used in basic and translational research and complements the STR Profiling Service.
In 2018, Konica Minolta, Inc., launched Konica Minolta Precision Medicine Japan, Inc., which is a 100%-owned subsidiary of Konica Minolta with responsibility for marketing high-end precision medicine tools and diagnostic services in Japan. Precision medicine is medical care that uses genetic and molecular profiling to optimize treatment for specific groups of patients.
In 2016, GENESIS, launched mycoplasma pneumonia antigen rapid diagnostic test kit, this kit detects the antigen of P1 gene of M. pneumonia from the specimen collected from the suspicious patients infected by M. pneumonia.
In 2015, Merck acquired Sigma-Aldrich Co., one of the global leaders in the life science sector to expand its product offering and through this acquisition, the company offers product into mycoplasma diagnostics device market
Mycoplasma Diagnostics Device Market-Taxonomy
The global Mycoplasma Diagnostics device market is segmented based on techniques, end-users, and regions
- Polymerase Chain Reaction (PCR)
- ELISA (Enzyme-linked immune sorbent assay)
- RIA (Radio immunoassay)
- Microbial culture techniques
- DNA staining
- Diagnostic laboratories
- North America
- Latin America
- Asia Pacific
- Middle East
Get PDF Brochure with Latest Insights @ https://www.coherentmarketinsights.com/insight/request-pdf/763
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients to achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having an office at global financial capital in the U.S. and sales consultants in the United Kingdom and Japan. Our client base includes players from across various business verticals in over 150 countries worldwide. We pride ourselves in catering to clients across the length and width of the horizon, from Fortune 500 enlisted companies to not-for-profit organizations, and startups looking to establish a foothold in the market. We excel in offering unmatched actionable market intelligence across various industry verticals, including chemicals and materials, healthcare, and food & beverages, consumer goods, packaging, semiconductors, software and services, Telecom, and Automotive. We offer syndicated market intelligence reports, customized research solutions, and consulting services.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027